Overview

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced ovarian cancer that is refractory to, or has recurred following, prior chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Pertuzumab